Percutaneous ethanol injection, radiofrequency and their combination in treatment of hepatocellular carcinoma

doi:10.3748/wjg.v11.i40.6277

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 40

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3146)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series.

Item

Count

PDF

325

HTML

2493

Figures (1-4)

328

Sum=3146

Oct 28, 2005 (publication date) through Feb 18, 2025

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Oct 28, 2005; 11(40): 6277-6280
Published online Oct 28, 2005. doi: 10.3748/wjg.v11.i40.6277

Full Size Figure Download Figure

Figure 3 HCC treated with TACE and RFA. A: Enhancement of the recurrent HCC after resection in the early arterial phase; B: After TACE, lesion restrained with iodine (red arrow) and an un-embolized feeding artery (yellow arrow) in the arterial phase; C: After RFA, no enhancement in the lesion in the early arterial phase (red arrow) and enhancement in the inner part of the lesion (yellow arrows) indicating incomplete necrosis.

Citation: Luo BM, Wen YL, Yang HY, Zhi H, Xiao XY, Ou B, Pan JS, Ma JH. Percutaneous ethanol injection, radiofrequency and their combination in treatment of hepatocellular carcinoma. World J Gastroenterol 2005; 11(40): 6277-6280
URL: https://www.wjgnet.com/1007-9327/full/v11/i40/6277.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i40.6277